TrialBreast cancer research and treatment2022

Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.

Mario Campone et al.PubMed ↗Publisher ↗

No numbers read from the abstract.